Overview
Nanospectra is a private company founded by Dr. Jennifer West in 2002 in Houston, TX and largely funded from government grants. The company specializes in using gold-coated nanoshells to absorb near-IR light and destroy cancer tumor cells in a therapy dubbed Aurolase TM therapy. This method is quicker and more specific than chemotherapy and results in a substantial reduction of side effects. Aurolase TM therapy is currently in Phase I of clinical testing and is currently seeking FDA permission to enter Phase II clinical testing in human patients with head and neck cancer.
Nanospectra.com
Recent News
11.02.2006- Nanospetra sold $1.7M of series A preferred stock in order to fund pilot trials for Phase II of the Aurolase TM therapy.
Collaborations
2007- Nanospectra received $1.25M from the Texas Emerging Technologies Fund (TETF) and $500K from the National Science foundation (NSF) to continue development and testing of the Aurolase TM cancer therapy.
2005- Nanospectra received $392K from the NSF for cancer research and $750K from the US Air Force to research nanoshell applications in detecting harmful biological and chemical agents.
2004- Nanospectra received $428K from the National Institute of Health (NIH) to research nanoshell detection of plaques related to Alzheimer's disease and $2M from the NIST ATP award for cancer treatment.
About Me
- W Raasch
- I am currently a graduate student at the Keck Graduate Institute for business and biotechnology. In addition to studying advances in nanotechnology, I am networking as much as possible and enjoying learning the many intricacies that go into running a modern day biotechnology company. If you have an idea, question, comment, or simply wish to network, do not hesitate to shoot me an email.
No comments:
Post a Comment